Other indications (e.g. myeloproliferative diseases)
other systemic therapies
The primary objective of this phase 2 trial is a first evaluation of the efficacy of combined treatment of ruxolitinib and ECP for patients with SR-cGvHD as assessed by Overall Response Rate (ORR) at the week 25 (Cycle 7 Day 1) visit. As secondary endpoints, changes in the modified Lee Symptom Scale score and failure-free-survival will be evaluated.
The primary objective of this phase 2 trial is a first evaluation of the efficacy of combined treatment of ruxolitinib and ECP for patients with SR-cGvHD as assessed by Overall Response Rate (ORR) at the week 25 (Cycle 7 Day 1) visit. As secondary endpoints, changes in the modified Lee Symptom Scale score and failure-free-survival will be evaluated.
